Laquinimod Tied to Reduced Relapses, Disability Progression in Some RRMS Patients
VANCOUVER, BC—Among patients with relapse-remitting MS (RRMS) with expanded disability status scale (EDSS) scores of >3, once-daily laquinimod (LAQ) 0.6mg can reduce annualized relapse rates (ARR) and confirmed disability progression (CDP), according to authors of a post-hoc analysis presented during a poster session at the 68th AAN Annual Meeting.
“These findings support the beneficial effects of LAQ in RRMS and provide rationale for ongoing evaluation of this drug in progressive forms of MS,” reported Timothy L. Vollmer, MD, University of Colorado, Aurora, CO, and coauthors.
“LAQ demonstrated significant benefits in relapse, disability, and MRI outcomes in patients with baseline EDSS >3,” the researchers wrote.
In order to assess the clinical efficacy of LAQ 0.6mg once-daily versus placebo among patients with RRMS, the authors analyzed a subset of data pooled from the ALLEGRO and BRAVO clinical trials, for 655 patients with EDSS >3 (of whom 327 had been assigned to the placebo study group and 328 were randomly assigned to the LAQ 0.6 mg once-daily study group).
“In worsening MS patients with an EDSS >3 at baseline, LAQ demonstrated substantial benefits compared with placebo on relapse, disability progression, ambulation, and brain atrophy,” the authors reported. “Compared with placebo, LAQ reduced ARR by 25% (P=0.012), 3-month CDP by 40% (P=0.023), and 6-month CDP by 53% (P=0.0083).”
The 53% reduction in 6-month CDP was "further substantiated" by a significant MS Functional Composite (MSFC) LAQ-associated benefit at Month 24 (P=0.0009). That was largely attributable to a 59% improvement vs. placebo on the T25FW performance, the research team noted.
Dr. Vollmer disclosed receiving compensation for his participation in the BRAVO study.